<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8449700</PMID>
        <DateCreated>
            <Year>1993</Year>
            <Month>04</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1993</Year>
            <Month>04</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2006</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0017-8470</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>44</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1993</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete</Title>
                <ISOAbbreviation>Hautarzt</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Contact allergy to topical glucocorticoids].</ArticleTitle>
            <Pagination>
                <MedlinePgn>91-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Three women with suspected contact allergies to topical corticosteroids had positive patch test reactions to amcinonide, triamcinolone acetonide and budesonide, two of them also reacted to tixocortol pivalate. Doubtful patch test results were seen on hydrocortisone and Alfasone cream. On performing a ROAT (repeated open application test) with amcinonide in all women we saw massive erythematous reactions and spreading urticaria. ROAT with Betnesol-V cream was negative. Two of the women, who were older, had multiple sensitization owing to long-term treatment of venous ulcers over many years. The third woman was young and had acquired the allergy through short-term treatment of prurigo with various topical corticosteroids. Contact allergy to topical corticosteroids is frequent and should be borne in mind in daily practice. Especially when chronic dermatitis is difficult to manage, cross reactions between chemically related corticosteroids should be considered.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fedler</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hautklinik Städtischen Kliniken Dortmund.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pilz</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Frosch</LastName>
                    <ForeName>P J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
            </AuthorList>
            <Language>ger</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Kontaktallergie auf topische Glukokortikoide.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>GERMANY</Country>
            <MedlineTA>Hautarzt</MedlineTA>
            <NlmUniqueID>0372755</NlmUniqueID>
            <ISSNLinking>0017-8470</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Hautarzt. 1994 Mar;45(3):196</RefSource>
                <PMID Version="1">8175354</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000287">Administration, Topical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003875">Drug Eruptions</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005938">Glucocorticoids</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010328">Patch Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1993</Year>
                <Month>2</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1993</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1993</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8449700</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">835515</PMID>
        <DateCreated>
            <Year>1977</Year>
            <Month>03</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1977</Year>
            <Month>03</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-922X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>131</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1977</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of diseases of children (1960)</Title>
                <ISOAbbreviation>Am. J. Dis. Child.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Athetosis and phenytoin toxicity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>105</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Buchanan</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosen</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rabinowitz</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Am J Dis Child</MedlineTA>
            <NlmUniqueID>0370471</NlmUniqueID>
            <ISSNLinking>0002-922X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>6158TKW0C5</RegistryNumber>
                <NameOfSubstance UI="D010672">Phenytoin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001264">Athetosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004827">Epilepsy</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010672">Phenytoin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1977</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1977</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1977</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">835515</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16849620</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>08</Month>
            <Day>02</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>02</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1060-0280</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>40</Volume>
                    <Issue>7-8</Issue>
                    <PubDate>
                        <MedlineDate>2006 Jul-Aug</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>The Annals of pharmacotherapy</Title>
                <ISOAbbreviation>Ann Pharmacother</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Long QTc interval and torsade de pointes caused by fluconazole.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1456-61</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe a patient who developed torsade de pointes while being treated with fluconazole.</AbstractText>
                <AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 33-year-old woman with a 5 year history of systemic lupus erythematosus was admitted to the intensive care unit because of respiratory insufficiency due to Candida albicans pneumonia. Therapy with intravenous fluconazole 200 mg/day, with dose later adjusted according to her renal function, was started. Prolongation of the QTc interval and torsade de pointes occurred. Initially, domperidone, which had been initiated the day before fluconazole, was suspected as the possible cause and was discontinued; ultimately, both drugs were discontinued. However, torsade de pointes recurred several weeks later when the patient was treated with fluconazole for a second time and disappeared again on withdrawal of the drug. According to the Naranjo probability scale, this adverse reaction was highly probable.</AbstractText>
                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The risk of torsade de pointes does not correlate in a linear fashion with prolongation of the QTc interval, but an interval beyond 500 msec is considered a significant risk factor. Given that both fluconazole and domperidone are metabolized by the cytochrome P450 system, they may intensify each other's proarrhythmic effects, particularly in patients with concurrent renal dysfunction. These risks are of particular concern in patients whose baseline QTc interval is prolonged for any reason.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">From the case history, as well as use of the Naranjo scale, we concluded that fluconazole was the highly probable cause of the development of torsade de pointes in our patient.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pham</LastName>
                    <ForeName>C Phu</ForeName>
                    <Initials>CP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Intensive Care, Twenteborg Hospital Almelo, Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Feiter</LastName>
                    <ForeName>Peter W</ForeName>
                    <Initials>PW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van der Kuy</LastName>
                    <ForeName>P Hugo M</ForeName>
                    <Initials>PH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Mook</LastName>
                    <ForeName>Walther Nka</ForeName>
                    <Initials>WN</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2006</Year>
                <Month>07</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Pharmacother</MedlineTA>
            <NlmUniqueID>9203131</NlmUniqueID>
            <ISSNLinking>1060-0280</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5587267Z69</RegistryNumber>
                <NameOfSubstance UI="D004294">Domperidone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8VZV102JFY</RegistryNumber>
                <NameOfSubstance UI="D015725">Fluconazole</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000935">Antifungal Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001992">Bronchoalveolar Lavage Fluid</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002177">Candidiasis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004294">Domperidone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015725">Fluconazole</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008133">Long QT Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011014">Pneumonia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016171">Torsades de Pointes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2006</Year>
                <Month>7</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>7</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>2</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>7</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">aph.1G741</ArticleId>
            <ArticleId IdType="doi">10.1345/aph.1G741</ArticleId>
            <ArticleId IdType="pubmed">16849620</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12174440</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>08</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>11</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0028-2162</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>146</Volume>
                    <Issue>30</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Jul</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nederlands tijdschrift voor geneeskunde</Title>
                <ISOAbbreviation>Ned Tijdschr Geneeskd</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Severe parkinsonism due to metoclopramide in a patient with polypharmacy].</ArticleTitle>
            <Pagination>
                <MedlinePgn>1430-1</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Habets</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>dut</Language>
            <PublicationTypeList>
                <PublicationType UI="D016420">Comment</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Ernstig parkinsonisme ten gevolge van metoclopramide bij een patiënte met polyfarmacie.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Ned Tijdschr Geneeskd</MedlineTA>
            <NlmUniqueID>0400770</NlmUniqueID>
            <ISSNLinking>0028-2162</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>L4YEB44I46</RegistryNumber>
                <NameOfSubstance UI="D008787">Metoclopramide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentOn">
                <RefSource>Ned Tijdschr Geneeskd. 2002 Jan 26;146(4):175-7</RefSource>
                <PMID Version="1">11845569</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018492">Dopamine Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008787">Metoclopramide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010302">Parkinson Disease, Secondary</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019338">Polypharmacy</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12174440</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">14654219</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>12</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>07</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2008</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0925-4773</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>120</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Mechanisms of development</Title>
                <ISOAbbreviation>Mech. Dev.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Msx1/Bmp4 genetic pathway regulates mammalian alveolar bone formation via induction of Dlx5 and Cbfa1.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1469-79</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In the developing mammalian tooth, the cranial neural crest derived dental mesenchyme consists of the dental papilla and dental follicle. The dental papilla gives rise to odontoblasts and dental pulp and the dental follicle gives rise to the periodontium, including the osteoblasts that contribute to the alveolar process. The alveolar process is a specialized intramembranous bone that forms the primary support structure for the dentition. The Msx1 gene controls many aspects of craniofacial development, as evidenced by craniofacial abnormalities seen in Msx1(-/-) mice, including the arrest of tooth development and the absence of the alveolar bone. Previous studies demonstrated that ectopic expression of Bmp4, a downstream target of Msx1, in the Msx1(-/-) dental mesenchyme rescued alveolar bone formation. Here we confirm an early requirement of BMP activity for alveolar bone formation. We show that the expression of Cbfa1 and Dlx5, two genes encode transcription factors that are critical for bone differentiation, overlaps with that of Msx1 and Bmp4 in the developing tooth and alveolar process. We have demonstrated that Dlx5 and Cbfa1 expression is down-regulated in Msx1(-/-) dental mesenchyme and that Msx1 and Bmp4 expression are unaltered in Cbfa1(-/-) mice. These data place Dlx5 and Cbfa1 downstream from the Msx1/Bmp4 in the genetic pathway that regulates tooth development. Ectopic expression of Bmp4 in Msx1 mutants restores the expression of Dlx5, but not Cbfa1, in the dental mesenchyme, and rescues the expression of both Dlx5 and Cbfa1 in the developing alveolar bone. Therefore, the early expression of Cfba1 in the dental mesenchyme appears dispensable for the development of the alveolar bone. Taken together with in vitro gene induction studies, our results demonstrate that BMP4 controls Dlx5 expression in dental mesenchyme, and functions upstream to both Dlx5 and Cbfa1 to regulate alveolar bone formation during tooth development.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Zunyi</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cell and Molecular Biology, Tulane University, 2000 Stern Hall, 6400 Freret St, New Orleans, LA 70118, USA. zzhang 1@tulane.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Yiqiang</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiaoyun</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Jean</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jinkun</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>YiPing</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01DE11088</GrantID>
                    <Acronym>DE</Acronym>
                    <Agency>NIDCR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01DE12329</GrantID>
                    <Acronym>DE</Acronym>
                    <Agency>NIDCR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01DE14044</GrantID>
                    <Acronym>DE</Acronym>
                    <Agency>NIDCR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Mech Dev</MedlineTA>
            <NlmUniqueID>9101218</NlmUniqueID>
            <ISSNLinking>0925-4773</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C525810">Bmp4 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D055415">Bone Morphogenetic Protein 4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019485">Bone Morphogenetic Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050659">Core Binding Factor Alpha 1 Subunit</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C501120">Dlx5 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051957">MSX1 Transcription Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000539">Alveolar Process</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055415">Bone Morphogenetic Protein 4</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019485">Bone Morphogenetic Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050659">Core Binding Factor Alpha 1 Subunit</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004843">Epistasis, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017353">Gene Deletion</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005816">Genetic Complementation Test</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051957">MSX1 Transcription Factor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008648">Mesoderm</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015533">Transcriptional Activation</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>12</Month>
                <Day>5</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>7</Month>
                <Day>29</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>12</Month>
                <Day>5</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14654219</ArticleId>
            <ArticleId IdType="pii">S0925477303002181</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20456060</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>07</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>10</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-9592</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Paediatric anaesthesia</Title>
                <ISOAbbreviation>Paediatr Anaesth</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The effect of a 3 : 1 volume mixture of propofol 1% and thiopental 2.5% in reducing the pain on injection of propofol in children.</ArticleTitle>
            <Pagination>
                <MedlinePgn>545-52</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1460-9592.2010.03318.x</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In this prospective, randomized, double-blind, controlled trial, our primary objective was to assess the effect of a 3 : 1 mixture of propofol and thiopental in reducing pain on injection in children. Our hypothesis was that a 3 : 1 mixture of propofol and thiopental (treatment) would reduce the incidence of pain on injection to 20% compared to the expected incidence of 40% in the control group of an 11 : 1 mixture of propofol and 2% lidocaine.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Study subjects were patients 12-17 years old who were scheduled to undergo surgery and general anesthesia. Pain was assessed by a single-blinded observer present in the operating room. The major statistical method used in the analysis was multiple logistic regression.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 164 children analyzed, 96 patients (58.5%) were male. The average age was 14.3 (sd = 1.65). The incidence of pain in the control group was 32.1% (26/81), compared to 25.3% (21/83) in the treatment group. The logistic regression analysis showed that there was not sufficient evidence that the treatment group was better than control group in reducing pain (P = 0.24). There were no significant differences in postoperative recovery time, nausea, vomiting, or blood pressure between the two groups (all P values &gt;0.10).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There was not sufficient evidence to show that a 3 : 1 mixture of propofol and thiopental was better than an 11 : 1 volume admixture of propofol and lidocaine in reducing the incidence of pain on injection to 20%.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fahringer</LastName>
                    <ForeName>David L</ForeName>
                    <Initials>DL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nemours Children's Clinic, Jacksonville, FL 32207, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goodwin</LastName>
                    <ForeName>Salvatore R</ForeName>
                    <Initials>SR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Warde</LastName>
                    <ForeName>Mary K</ForeName>
                    <Initials>MK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ye</LastName>
                    <ForeName>Gang</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blackwelder</LastName>
                    <ForeName>Bryan</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ajala</LastName>
                    <ForeName>Adebisi M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gurgis</LastName>
                    <ForeName>Fahmy S</ForeName>
                    <Initials>FS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>04</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Paediatr Anaesth</MedlineTA>
            <NlmUniqueID>9206575</NlmUniqueID>
            <ISSNLinking>1155-5645</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019162">Anesthetics, Combined</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018686">Anesthetics, Intravenous</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>76-75-5</RegistryNumber>
                <NameOfSubstance UI="D013874">Thiopental</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>R60L0SM5BC</RegistryNumber>
                <NameOfSubstance UI="D008874">Midazolam</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YI7VU623SF</RegistryNumber>
                <NameOfSubstance UI="D015742">Propofol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000465">Algorithms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D019162">Anesthetics, Combined</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018686">Anesthetics, Intravenous</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006339">Heart Rate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006993">Hypnotics and Sedatives</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007275">Injections, Intravenous</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016015">Logistic Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008874">Midazolam</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016017">Odds Ratio</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010146">Pain</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010147">Pain Measurement</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011229">Preanesthetic Medication</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015742">Propofol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018401">Sample Size</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D013874">Thiopental</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2010</Year>
                <Month>4</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>5</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>5</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">PAN3318</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1460-9592.2010.03318.x</ArticleId>
            <ArticleId IdType="pubmed">20456060</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16012952</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>07</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>09</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0016-5085</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>129</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Gastroenterology</Title>
                <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cell type-specific intervention of transforming growth factor beta/Smad signaling suppresses collagen gene expression and hepatic fibrosis in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>259-68</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">Transforming growth factor beta and its intracellular mediators, Smad proteins, play important roles in stimulating collagen gene transcription and, thus, could be the targets for treating hepatic fibrosis. However, intervention of transforming growth factor beta/Smad signaling affects physiological signal transduction as well and may cause serious adverse effects on clinical application. Here we have attempted to suppress hepatic fibrosis by expressing a transforming growth factor beta/Smad antagonist selectively in collagen-producing cells only in the fibrotic liver.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Recombinant adenoviruses expressing either green fluorescent protein or a transforming growth factor beta/Smad signal repressor, YB-1, were injected into mice untreated or treated with carbon tetrachloride. Green fluorescent protein expression was analyzed under a confocal laser scanning microscope. Antifibrotic effects of YB-1 overexpression were examined by luciferase assays and histological examination with transgenic reporter mice.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">When the CAG expression unit was used as a control, green fluorescent protein was strongly expressed in a large number of hepatocytes in both normal and carbon tetrachloride-treated liver. In contrast, green fluorescent protein expression driven by a tissue-specific enhancer of the mouse alpha2(I) collagen gene ( COL1A2 ) was detected in activated hepatic stellate cells in carbon tetrachloride-induced fibrotic liver, but not in untreated normal liver. No green fluorescent protein fluorescence was observed in any other organs when the COL1A2 enhancer was used. Adenovirus-mediated YB-1 expression under the control of the COL1A2 enhancer significantly decreased COL1A2 promoter activity after carbon tetrachloride injection and subsequently suppressed the progression of hepatic fibrosis.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results validate a new concept of the therapy for hepatic fibrosis to achieve cell type-specific gene expression only in the fibrotic liver, with little damage to other organs.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Inagaki</LastName>
                    <ForeName>Yutaka</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Liver Fibrosis Research Unit, Department of Community Health, Tokai University School of Medicine, Isehara, Japan. yutakai@is.icc.u-tokai.ac.jp</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kushida</LastName>
                    <ForeName>Miwa</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Higashi</LastName>
                    <ForeName>Kiyoshi</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Itoh</LastName>
                    <ForeName>Johbu</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Higashiyama</LastName>
                    <ForeName>Reiichi</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hong</LastName>
                    <ForeName>Yun Yu</ForeName>
                    <Initials>YY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawada</LastName>
                    <ForeName>Norifumi</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Namikawa</LastName>
                    <ForeName>Kazuhiko</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kiyama</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bou-Gharios</LastName>
                    <ForeName>George</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watanabe</LastName>
                    <ForeName>Tetsu</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Okazaki</LastName>
                    <ForeName>Isao</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ikeda</LastName>
                    <ForeName>Kazuo</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Gastroenterology</MedlineTA>
            <NlmUniqueID>0374630</NlmUniqueID>
            <ISSNLinking>0016-5085</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D024042">Collagen Type I</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051785">Smad Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051840">Y-Box-Binding Protein 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C070856">YBX1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C118885">alpha 2(I) collagen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>147336-22-9</RegistryNumber>
                <NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>82115-62-6</RegistryNumber>
                <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-34-5</RegistryNumber>
                <NameOfSubstance UI="D003094">Collagen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>CL2T97X0V0</RegistryNumber>
                <NameOfSubstance UI="D002251">Carbon Tetrachloride</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000256">Adenoviridae</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002251">Carbon Tetrachloride</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003094">Collagen</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D024042">Collagen Type I</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004742">Enhancer Elements, Genetic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015316">Genetic Therapy</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D049452">Green Fluorescent Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007371">Interferon-gamma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008103">Liver Cirrhosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051785">Smad Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015534">Trans-Activators</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051840">Y-Box-Binding Protein 1</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>7</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>9</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>7</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0016508505008930</ArticleId>
            <ArticleId IdType="pubmed">16012952</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">7738211</PMID>
        <DateCreated>
            <Year>1995</Year>
            <Month>06</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1995</Year>
            <Month>06</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0091-2700</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>34</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>1994</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of clinical pharmacology</Title>
                <ISOAbbreviation>J Clin Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Calcium-channel entry blocker therapy for hypertensive patients with concomitant renal impairment: a focus on isradipine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1164-72</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In the treatment of hypertension in renally impaired patients, normalization of blood pressure alone may not be sufficient to prevent significant morbidity to the kidneys. Treatment must reduce pressure in the renal vasculature, otherwise glomerular filtration rate and renal plasma flow will continue to deteriorate. Isradipine a dihydropyridine calcium-channel blocker, has been investigated as a suitable treatment in this setting. Isradipine maintains glomerular filtration rate, preserves or enhances renal plasma flow, decreases renal vascular resistance, maintains or reduces filtration fraction, and exerts a sustained natriuretic effect, all of which may enable isradipine to slow the rate of progression of renal deterioration. In addition, isradipine may decrease proteinuria and may decrease glomerular capillary pressure by dilating both the efferent and afferent arterioles. Unlike older calcium-channel blockers, isradipine exhibits minimal cardiodepressant activity and is not associated with any negative inotropic effects. It is metabolized in the liver and dosage adjustments may not be necessary when administered to patients with renal insufficiency. Isradipine has a favorable renal effect profile and also has several properties that meet the requirements of other patient populations where an extra measure of antihypertensive safety is required, such as diabetics, dialysis patients, and transplant recipients. Side effects with isradipine are usually mild and transient, occurring in a dose-dependent manner.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Frishman</LastName>
                    <ForeName>W H</ForeName>
                    <Initials>WH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Clin Pharmacol</MedlineTA>
            <NlmUniqueID>0366372</NlmUniqueID>
            <ISSNLinking>0091-2700</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YO1UK1S598</RegistryNumber>
                <NameOfSubstance UI="D017275">Isradipine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002121">Calcium Channel Blockers</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D048909">Diabetes Complications</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005919">Glomerular Filtration Rate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006439">Hemodynamics</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017275">Isradipine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>75</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1994</Year>
                <Month>12</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1994</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1994</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7738211</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23060367</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>12</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>01</Month>
            <Day>10</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1552-9924</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>120</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Environmental health perspectives</Title>
                <ISOAbbreviation>Environ. Health Perspect.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Arsenic reduction in drinking water and improvement in skin lesions: a follow-up study in Bangladesh.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1733-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1289/ehp.1205381</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Chronic exposure to arsenic is associated with skin lesions. However, it is not known whether reducing arsenic exposure will improve skin lesions.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We evaluated the association between reduced arsenic exposures and skin lesion recovery over time.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A follow-up study of 550 individuals was conducted in 2009-2011 on a baseline population of skin lesion cases (n = 900) previously enrolled in Bangladesh in 2001-2003. Arsenic in drinking water and toenails, and skin lesion status and severity were ascertained at baseline and follow-up. We used logistic regression and generalized estimating equation (GEE) models to evaluate the association between log10-transformed arsenic exposure and skin lesion persistence and severity.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">During the study period, water arsenic concentrations decreased in this population by 41% overall, and 65 individuals who had skin lesions at baseline had no identifiable lesions at follow-up. In the adjusted models, every log10 decrease in water arsenic and toenail arsenic was associated with 22% [odds ratio (OR) = 1.22; 95% CI: 0.85, 1.78] and 4.5 times (OR = 4.49; 95% CI: 1.94, 11.1) relative increase in skin lesion recovery, respectively. In addition, lower baseline arsenic levels were significantly associated with increased odds of recovery. A log10 decrease in toenail arsenic from baseline to follow-up was also significantly associated with reduced skin lesion severity in cases over time (mean score change of -5.22 units; 95% CI: -8.61, -1.82).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Reducing arsenic exposure increased the odds that an individual with skin lesions would recover or show less severe lesions within 10 years. Reducing arsenic exposure must remain a public health priority in Bangladesh and in other regions affected by arsenic-contaminated water.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Seow</LastName>
                    <ForeName>Wei Jie</ForeName>
                    <Initials>WJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pan</LastName>
                    <ForeName>Wen-Chi</ForeName>
                    <Initials>WC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kile</LastName>
                    <ForeName>Molly L</ForeName>
                    <Initials>ML</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baccarelli</LastName>
                    <ForeName>Andrea A</ForeName>
                    <Initials>AA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Quamruzzaman</LastName>
                    <ForeName>Quazi</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rahman</LastName>
                    <ForeName>Mahmuder</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mahiuddin</LastName>
                    <ForeName>Golam</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mostofa</LastName>
                    <ForeName>Golam</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Xihong</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Christiani</LastName>
                    <ForeName>David C</ForeName>
                    <Initials>DC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>K01 ES017800</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K01 ES017800</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 ES00002</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P42 E016454</GrantID>
                    <Agency>PHS HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P42 ES016454</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 ES015533</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 ES007069</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Environ Health Perspect</MedlineTA>
            <NlmUniqueID>0330411</NlmUniqueID>
            <ISSNLinking>0091-6765</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D060766">Drinking Water</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014874">Water Pollutants, Chemical</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>N712M78A8G</RegistryNumber>
                <NameOfSubstance UI="D001151">Arsenic</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Toxicol Clin Toxicol. 2001;39(7):683-700</RefSource>
                <PMID Version="1">11778666</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Causes Control. 2001 Dec;12(10):909-16</RefSource>
                <PMID Version="1">11808710</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bull World Health Organ. 2002;80(2):173</RefSource>
                <PMID Version="1">11953799</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cytogenet Genome Res. 2004;104(1-4):359-64</RefSource>
                <PMID Version="1">15162065</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2004 Aug 1;198(3):291-6</RefSource>
                <PMID Version="1">15276408</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 1968 Mar;40(3):453-63</RefSource>
                <PMID Version="1">5644201</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 1977 Aug;19:109-19</RefSource>
                <PMID Version="1">908285</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 1982 Jun;45(6):904-11</RefSource>
                <PMID Version="1">6212076</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1984 Mar 10;1(8376):530-3</RefSource>
                <PMID Version="1">6142253</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Indian J Med Res. 1987 Mar;85:326-34</RefSource>
                <PMID Version="1">2956191</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Epidemiol. 1989 Dec;130(6):1123-32</RefSource>
                <PMID Version="1">2589305</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Epidemiol. 1992 Aug 15;136(4):417-21</RefSource>
                <PMID Version="1">1415161</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1996 Oct 11;274(5285):174-5</RefSource>
                <PMID Version="1">8927976</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Analyst. 1998 Mar;123(3):441-5</RefSource>
                <PMID Version="1">9659705</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Epidemiol. 1998 Aug;27(4):561-9</RefSource>
                <PMID Version="1">9758107</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Epidemiology. 2005 Jan;16(1):82-6</RefSource>
                <PMID Version="1">15613949</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Occup Environ Med. 2005 Oct;47(10):1026-35</RefSource>
                <PMID Version="1">16217243</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Expo Sci Environ Epidemiol. 2006 Mar;16(2):191-205</RefSource>
                <PMID Version="1">16160703</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):902-7</RefSource>
                <PMID Version="1">16702368</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Clin Nutr. 2006 Nov;84(5):1093-101</RefSource>
                <PMID Version="1">17093162</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Health Popul Nutr. 2006 Sep;24(3):363-75</RefSource>
                <PMID Version="1">17366778</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Clin Nutr. 2007 May;85(5):1367-74</RefSource>
                <PMID Version="1">17490975</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2007 Jun;115(6):917-23</RefSource>
                <PMID Version="1">17589600</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Clin Nutr. 2007 Oct;86(4):1202-9</RefSource>
                <PMID Version="1">17921403</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Cancer. 2008 Jul 15;123(2):283-7</RefSource>
                <PMID Version="1">18386817</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Int. 2009 Apr;35(3):647-54</RefSource>
                <PMID Version="1">19110310</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2009 Sep 1;239(2):184-92</RefSource>
                <PMID Version="1">19371619</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Food Chem Toxicol. 2010 May;48(5):1234-8</RefSource>
                <PMID Version="1">20170701</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Exp Toxicol. 2010 Jun;29(6):513-24</RefSource>
                <PMID Version="1">20056736</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Environ Sci Eng. 2010 Apr;52(2):147-54</RefSource>
                <PMID Version="1">21114123</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Epidemiol. 2011 Jul 15;174(2):185-94</RefSource>
                <PMID Version="1">21576319</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2012 Mar;187(3):856-61</RefSource>
                <PMID Version="1">22248521</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>IARC Monogr Eval Carcinog Risks Hum. 2004;84:1-477</RefSource>
                <PMID Version="1">15645577</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001151">Arsenic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D001459">Bangladesh</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D060766">Drinking Water</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004781">Environmental Exposure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004784">Environmental Monitoring</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016014">Linear Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016015">Logistic Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013058">Mass Spectrometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009262">Nails</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012871">Skin Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014874">Water Pollutants, Chemical</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC3548283</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>4</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>5</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1289/ehp.1205381</ArticleId>
            <ArticleId IdType="pubmed">23060367</ArticleId>
            <ArticleId IdType="pmc">PMC3548283</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20069278</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>09</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>04</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1433-2965</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>21</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</Title>
                <ISOAbbreviation>Osteoporos Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Synergistic effects of green tea polyphenols and alphacalcidol on chronic inflammation-induced bone loss in female rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1841-52</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00198-009-1122-8</ELocationID>
            <Abstract>
                <AbstractText Label="UNLABELLED">Studies suggest that green tea polyphenols (GTP) or alphacalcidol is promising agent for preventing bone loss. Findings that GTP supplementation plus alphacalcidol administration increased bone mass via a decrease of oxidative stress and inflammation suggest a significant role of GTP plus alphacalcidol in bone health of patients with chronic inflammation.</AbstractText>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Studies have suggested that green tea polyphenols (GTP) or alphacalcidol are promising dietary supplements for preventing bone loss in women. However, the mechanism(s) related to the possible osteo-protective role of GTP plus D(3) in chronic inflammation-induced bone loss is not well understood.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This study evaluated bioavailability, efficacy, and related mechanisms of GTP in combination with alphacalcidol in conserving bone loss in rats with chronic inflammation. A 12-week study of 2 (no GTP vs. 0.5% GTP in drinking water) × 2 (no alphacalcidol vs. 0.05 μg/kg alphacalcidol, 5×/week) factorial design in lipopolysaccharide-administered female rats was performed. In addition, a group receiving placebo administration was used to compare with a group receiving lipopolysaccharide administration only to evaluate the effect of lipopolysaccharide.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Lipopolysaccharide administration resulted in lower values for bone mass, but higher values for serum tartrate-resistant acid phosphatase (TRAP), urinary 8-hydroxy-2'-deoxyguanosine, and mRNA expression of tumor necrosis factor-α and cyclooxygenase-2 in spleen. GTP supplementation increased urinary epigallocatechin and epicatechin concentrations. Both GTP supplementation and alphacalcidol administration resulted in a significant increase in bone mass, but a significant decrease in serum TRAP levels, urinary 8-hydroxydeoxyguanosine levels, and mRNA expression of tumor necrosis factor-α and cyclooxygenase-2 in spleen. A synergistic effect of GTP and alphacalcidol was observed in these parameters. Neither GTP nor alphacalcidol affected femoral bone area or serum osteocalcin.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We conclude that a bone-protective role of GTP plus alphacalcidol during chronic inflammation bone loss may be due to a reduction of oxidative stress damage and inflammation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>C-L</ForeName>
                    <Initials>CL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Texas Tech University Health Sciences Center, BB 198, 3601 4th street, Lubbock, TX 79430-9097, USA. leslie.shen@ttuhsc.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yeh</LastName>
                    <ForeName>J K</ForeName>
                    <Initials>JK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cao</LastName>
                    <ForeName>J J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tatum</LastName>
                    <ForeName>O L</ForeName>
                    <Initials>OL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dagda</LastName>
                    <ForeName>R Y</ForeName>
                    <Initials>RY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>J-S</ForeName>
                    <Initials>JS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>CA90997</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R21AT003735</GrantID>
                    <Acronym>AT</Acronym>
                    <Agency>NCCAM NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>01</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Osteoporos Int</MedlineTA>
            <NlmUniqueID>9100105</NlmUniqueID>
            <ISSNLinking>0937-941X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006887">Hydroxycholecalciferols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010636">Phenols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D059808">Polyphenols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013662">Tea</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>88847-89-6</RegistryNumber>
                <NameOfSubstance UI="C067134">8-oxo-7-hydrodeoxyguanosine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.99.1</RegistryNumber>
                <NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.99.1</RegistryNumber>
                <NameOfSubstance UI="C489691">Ptgs2 protein, rat</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>G9481N71RO</RegistryNumber>
                <NameOfSubstance UI="D003849">Deoxyguanosine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>URQ2517572</RegistryNumber>
                <NameOfSubstance UI="C008088">alfacalcidol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Osteoporos Int. 2007 Mar;18(3):251-9</RefSource>
                <PMID Version="1">17151836</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Arch Allergy Immunol. 2007;143(1):31-48</RefSource>
                <PMID Version="1">17191007</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr Biochem. 2007 May;18(5):341-7</RefSource>
                <PMID Version="1">16963251</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Orthop Sci. 2007 Jul;12(4):317-20</RefSource>
                <PMID Version="1">17657549</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr Sci Vitaminol (Tokyo). 2007 Jun;53(3):191-7</RefSource>
                <PMID Version="1">17874822</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Clin Nutr. 2007 Oct;86(4):1243-7</RefSource>
                <PMID Version="1">17921409</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Rheumatol Int. 2007 Dec;28(2):103-11</RefSource>
                <PMID Version="1">17668216</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Food Chem Toxicol. 2008 Jan;46(1):232-40</RefSource>
                <PMID Version="1">17888558</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Calcif Tissue Int. 2008 Feb;82(2):127-36</RefSource>
                <PMID Version="1">18175034</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr Sci Vitaminol (Tokyo). 2008 Feb;54(1):11-7</RefSource>
                <PMID Version="1">18388402</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Osteoporos Int. 2008 Jul;19(7):979-90</RefSource>
                <PMID Version="1">18084689</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2008 Jul;149(7):3264-6</RefSource>
                <PMID Version="1">18483146</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Periodontol. 2008 Aug;79(8 Suppl):1569-76</RefSource>
                <PMID Version="1">18673012</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Calcif Tissue Int. 2008 Aug;83(2):121-8</RefSource>
                <PMID Version="1">18543014</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Calcif Tissue Int. 2008 Jun;82(6):475-88</RefSource>
                <PMID Version="1">18509698</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Chem Lab Med. 2008;46(11):1550-5</RefSource>
                <PMID Version="1">18847368</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mediators Inflamm. 2008;2008:291808</RefSource>
                <PMID Version="1">19148296</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2009 Feb 20;379(4):1033-7</RefSource>
                <PMID Version="1">19150340</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bone. 2009 Apr;44(4):684-90</RefSource>
                <PMID Version="1">19118658</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Regul Integr Comp Physiol. 2009 May;296(5):R1376-84</RefSource>
                <PMID Version="1">19225144</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nutr Res. 2009 Jul;29(7):437-56</RefSource>
                <PMID Version="1">19700031</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Periodontal Res. 2010 Feb;45(1):23-30</RefSource>
                <PMID Version="1">19602116</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr Biochem. 2010 Oct;21(10):968-74</RefSource>
                <PMID Version="1">19962296</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Clin Nutr. 2000 Apr;71(4):1003-7</RefSource>
                <PMID Version="1">10731510</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2000 Apr 21;270(3):793-7</RefSource>
                <PMID Version="1">10772904</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr. 2000 Sep;130(9):2274-84</RefSource>
                <PMID Version="1">10958824</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2000 Nov 9;408(6809):239-47</RefSource>
                <PMID Version="1">11089981</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Exp Gerontol. 2000 Oct;35(8):947-56</RefSource>
                <PMID Version="1">11121682</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Rheumatol Rep. 2000 Feb;2(1):53-61</RefSource>
                <PMID Version="1">11123040</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2001 Mar;142(3):1290-5</RefSource>
                <PMID Version="1">11181547</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Free Radic Biol Med. 2001 Aug 15;31(4):509-19</RefSource>
                <PMID Version="1">11498284</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Bone Miner Metab. 2001;19(5):277-86</RefSource>
                <PMID Version="1">11498729</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2001 Dec;44(12):2790-6</RefSource>
                <PMID Version="1">11762939</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bone. 2002 Feb;30(2):340-6</RefSource>
                <PMID Version="1">11856640</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2002 Mar 22;292(1):94-101</RefSource>
                <PMID Version="1">11890677</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Bone Miner Res. 2002 Apr;17(4):622-9</RefSource>
                <PMID Version="1">11918219</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Intern Med. 2002 May 13;162(9):1001-6</RefSource>
                <PMID Version="1">11996609</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 2003 May 19;197(10):1303-10</RefSource>
                <PMID Version="1">12743173</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Metabolism. 2003 May;52(5):579-85</RefSource>
                <PMID Version="1">12759887</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Gastroenterol. 2003 May;98(5):1094-100</RefSource>
                <PMID Version="1">12809833</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J UOEH. 2003 Jun 1;25(2):185-95</RefSource>
                <PMID Version="1">12813861</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Epidemiol. 2003 Oct 15;158(8):772-81</RefSource>
                <PMID Version="1">14561667</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Rheumatol. 2003 Nov;30(11):2365-8</RefSource>
                <PMID Version="1">14677178</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Bone Miner Metab. 2004;22(4):352-9</RefSource>
                <PMID Version="1">15221494</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Periodontol. 2004 Aug;31(8):596-603</RefSource>
                <PMID Version="1">15257734</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Rheumatol Int. 2004 Jul;24(4):189-97</RefSource>
                <PMID Version="1">15232715</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 2004 Sep;25(9):1567-74</RefSource>
                <PMID Version="1">15090467</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Periodontal Res. 2004 Oct;39(5):300-7</RefSource>
                <PMID Version="1">15324350</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bone. 2004 Sep;35(3):704-10</RefSource>
                <PMID Version="1">15336607</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1986 Sep 15;35(18):3091-4</RefSource>
                <PMID Version="1">3463305</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 1990 Mar;126(3):1654-9</RefSource>
                <PMID Version="1">2155107</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1990 Mar;85(3):632-9</RefSource>
                <PMID Version="1">2312718</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Bone Miner Res. 1993 Dec;8 Suppl 2:S505-10</RefSource>
                <PMID Version="1">7510095</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Bone Miner Res. 1995 Jul;10(7):1040-9</RefSource>
                <PMID Version="1">7484279</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Calcif Tissue Int. 1999 Oct;65(4):311-6</RefSource>
                <PMID Version="1">10485984</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Bone Miner Res. 2005 Jan;20(1):23-9</RefSource>
                <PMID Version="1">15619666</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncol Rep. 2005 Feb;13(2):253-7</RefSource>
                <PMID Version="1">15643507</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2005 Jun 24;280(25):24035-42</RefSource>
                <PMID Version="1">15834134</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Chim Acta. 2005 Oct;360(1-2):81-6</RefSource>
                <PMID Version="1">15970279</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Rheumatol Suppl. 2005 Sep;76:26-32</RefSource>
                <PMID Version="1">16142848</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Rheumatol Suppl. 2005 Sep;76:33-40</RefSource>
                <PMID Version="1">16142849</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Musculoskelet Neuronal Interact. 2005 Jul-Sep;5(3):273-84</RefSource>
                <PMID Version="1">16172518</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2005 Dec;146(12):5204-14</RefSource>
                <PMID Version="1">16150915</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2005 Dec;115(12):3318-25</RefSource>
                <PMID Version="1">16322775</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Osteoporos Int. 2005 Dec;16(12):2039-45</RefSource>
                <PMID Version="1">16170444</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 2006 Feb;27(2):262-8</RefSource>
                <PMID Version="1">15930028</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2006 Feb 15;55(1):15-8</RefSource>
                <PMID Version="1">16463406</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bone. 2006 Mar;38(3):378-86</RefSource>
                <PMID Version="1">16256450</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Adv Drug Deliv Rev. 2006 May 20;58(2):212-25</RefSource>
                <PMID Version="1">16567019</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cytokine Growth Factor Rev. 2006 Jun;17(3):203-16</RefSource>
                <PMID Version="1">16460988</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bone. 2006 Aug;39(2):325-35</RefSource>
                <PMID Version="1">16580896</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2006 Jul;91(7):2480-3</RefSource>
                <PMID Version="1">16608887</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1025-32</RefSource>
                <PMID Version="1">12376503</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii32-9</RefSource>
                <PMID Version="1">12379618</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Dent Res. 2003 Feb;82(2):82-90</RefSource>
                <PMID Version="1">12562878</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2006 Oct 1;216(1):11-9</RefSource>
                <PMID Version="1">16797629</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 2007 Jan 1;73(1):34-43</RefSource>
                <PMID Version="1">17034764</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):383-94</RefSource>
                <PMID Version="1">17214584</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001835">Body Weight</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015519">Bone Density</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050071">Bone Density Conservation Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001851">Bone Diseases, Metabolic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051546">Cyclooxygenase 2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003849">Deoxyguanosine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004326">Drinking</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004353">Drug Evaluation, Preclinical</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005419">Flavonoids</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006887">Hydroxycholecalciferols</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010636">Phenols</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008517">Phytotherapy</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059808">Polyphenols</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013154">Spleen</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D013662">Tea</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS189795</OtherID>
        <OtherID Source="NLM">PMC2919589</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>4</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00198-009-1122-8</ArticleId>
            <ArticleId IdType="pubmed">20069278</ArticleId>
            <ArticleId IdType="pmc">PMC2919589</ArticleId>
            <ArticleId IdType="mid">NIHMS189795</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20021290</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>12</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1744-764X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Expert opinion on drug safety</Title>
                <ISOAbbreviation>Expert Opin Drug Saf</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.</ArticleTitle>
            <Pagination>
                <MedlinePgn>9-14</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1517/14740330903413514</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Higher vancomycin concentrations are thought necessary for treatment of deep-seated methicillin-resistant Staphylococcus aureus (MRSA) infection, yet this may result in greater risk of nephrotoxicity. We evaluated the relationship of serum vancomycin trough concentration with clinical outcomes and nephrotoxicity for patients with deep-seated MRSA infection.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective cohort study evaluated adults with MRSA pneumonia, endocarditis or osteomyelitis who received vancomycin for &gt; or = 5 days from June 2005 to June 2007. Patients were stratified by mean vancomycin trough level [low (&lt; 15 mg/l), high (&gt; or = 15 mg/l)]. Outcomes were clinical response, mortality, length of stay (LOS) and nephrotoxicity. Three definitions of nephrotoxicity were used: i) rise in serum creatinine (SCr) &gt; or = 0.5 mg/dl; ii) 50% increase in SCr; and iii) 25% decrease in estimated creatinine clearance.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-five patients experiencing MRSA pneumonia (n = 28), endocarditis (n = 9), osteomyelitis (n = 20) and multiple infections (n = 2) were stratified into low (n = 39) and high (n = 16) groups. High group patients were more likely to be septic (p = 0.01) and have a higher APACHE II score (p = 0.01). After adjustment for APACHE II score, clinical response rates among survivors did not differ significantly. Risk of death was not significantly different between the high (19%) and low (5%) group patients (p = 0.1). LOS did not differ significantly between groups (p = 0.7). Nephrotoxicity occurred in the low and high groups, respectively, for 10 and 31% (p = 0.04) with definition 1, 10 and 31% (p = 0.04) with definition 2, and 13 and 25% (p = 0.1) with definition 3. After adjustment for APACHE II score, odds of nephrotoxicity based on definitions 1 or 2 were increased among the high versus low groups (OR = 3.27, 95% CI: 0.7 - 15.25, p = 0.1), although not statistically significant.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinical outcomes did not differ significantly between high and low trough groups for deep-seated MRSA infections. Nephrotoxicity was consistently higher in the high trough group, regardless of the definition used.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hermsen</LastName>
                    <ForeName>Elizabeth D</ForeName>
                    <Initials>ED</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Nebraska Medical Center, Department of Pharmaceutical and Nutrition Care, 984031 Omaha, NE 68918-4031, USA. ehermsen@nebraskamed.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hanson</LastName>
                    <ForeName>Monica</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sankaranarayanan</LastName>
                    <ForeName>Jayashri</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stoner</LastName>
                    <ForeName>Julie A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Florescu</LastName>
                    <ForeName>Marius C</ForeName>
                    <Initials>MC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rupp</LastName>
                    <ForeName>Mark E</ForeName>
                    <Initials>ME</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Expert Opin Drug Saf</MedlineTA>
            <NlmUniqueID>101163027</NlmUniqueID>
            <ISSNLinking>1474-0338</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6Q205EH1VU</RegistryNumber>
                <NameOfSubstance UI="D014640">Vancomycin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>AYI8EX34EU</RegistryNumber>
                <NameOfSubstance UI="D003404">Creatinine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000900">Anti-Bacterial Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003404">Creatinine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004697">Endocarditis, Bacterial</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007902">Length of Stay</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055624">Methicillin-Resistant Staphylococcus aureus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010019">Osteomyelitis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011023">Pneumonia, Staphylococcal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013203">Staphylococcal Infections</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014640">Vancomycin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>3</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14740330903413514</ArticleId>
            <ArticleId IdType="pubmed">20021290</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1732442</PMID>
        <DateCreated>
            <Year>1992</Year>
            <Month>02</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1992</Year>
            <Month>02</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0161-5505</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>33</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1992</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title>
                <ISOAbbreviation>J. Nucl. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>208-14</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function. Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy. The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week). There were no abnormalities or only isolated degeneration in the 1- or 2-wk treatment groups, isolated or scattered degeneration in half of the 3-wk group, frequent scattered degeneration in the 4-wk group, scattered or focal degeneration in the 5-wk group, and extensive degeneration in the 8-wk group. Myocardial accumulation of [125I]MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less. However, the 4-wk group had a slightly lower accumulation in the right ventricular wall (82% of the control) and significantly lower accumulation in the left ventricular wall (about 66% of the control: p less than 0.05). In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001). In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001). Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner. The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wakasugi</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cardiology, Pathology and Nuclear Medicine, Center for Adult Diseases, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wada</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hasegawa</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakano</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shibata</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Nucl Med</MedlineTA>
            <NlmUniqueID>0217410</NlmUniqueID>
            <ISSNLinking>0161-5505</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007462">Iodobenzenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013794">Thallium Radioisotopes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>35MRW7B4AD</RegistryNumber>
                <NameOfSubstance UI="D019797">3-Iodobenzylguanidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>80168379AG</RegistryNumber>
                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>X4W3ENH1CV</RegistryNumber>
                <NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>J Nucl Med. 1992 Feb;33(2):215-22</RefSource>
                <PMID Version="1">1732443</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019797">3-Iodobenzylguanidine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000320">Adrenergic Fibers</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001835">Body Weight</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000294">innervation</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006333">Heart Failure</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006352">Heart Ventricles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007457">Iodine Radioisotopes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007462">Iodobenzenes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009206">Myocardium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009638">Norepinephrine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011919">Rats, Inbred Strains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013794">Thallium Radioisotopes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1992</Year>
                <Month>2</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1992</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1992</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1732442</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10945867</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>09</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>09</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0022-3565</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>294</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2000</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of pharmacology and experimental therapeutics</Title>
                <ISOAbbreviation>J. Pharmacol. Exp. Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1112-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Neuronal nicotinic receptors are comprised of combinations of alpha(2-9) and beta(2-4) subunits arranged to form a pentameric receptor. Currently, the principal central nervous system (CNS) subtypes are believed to be alpha(4)beta(2) and a homomeric alpha(7) receptor, although other combinations almost certainly exist. The identity of the nicotinic receptor subtype(s) involved in the rewarding effects of nicotine are unknown. In the present study, using some recently described subtype selective nicotinic agonists and antagonists, we investigated the role of the alpha(7) nicotinic receptor in the mediation of nicotine-induced hyperactivity and self-administration in rats. The alpha(7) receptor agonists AR-R 17779 and DMAC failed to stimulate locomotor activity in both nicotine-nontolerant and -sensitized rats. In contrast, nicotine and the putative alpha(4)beta(2) subtype selective agonist SIB1765F increased activity in both experimental conditions. In nicotine-sensitized rats, the high affinity (including the alpha(4)beta(2) subtype) nicotinic antagonist dihydro-beta-erythroidine (DHbetaE), but not the selective alpha(7) antagonist methyllycaconitine (MLA), antagonized a nicotine-induced hyperactivity. Similarly, DHbetaE, but not MLA, pretreatment reduced nicotine self-administration. Electrophysiology experiments using Xenopus oocytes expressing the human alpha(7) receptor confirmed AR-R 17779 and DMAC to be potent agonists at this site, and further studies demonstrated the ability of systemically administered AR-R 17779 to penetrate into the CNS. Taken together, these results indicate a negligible role of alpha(7) receptors in nicotine-induced hyperlocomotion and reward in the rat, and support the view for an involvement of a member from the high-affinity nicotinic receptor subclass, possibly alpha(4)beta(2). Issues such as drug potency, CNS penetration, and desensitization of the alpha(7) receptor are discussed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Grottick</LastName>
                    <ForeName>A J</ForeName>
                    <Initials>AJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>PRBN, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trube</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Corrigall</LastName>
                    <ForeName>W A</ForeName>
                    <Initials>WA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huwyler</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malherbe</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wyler</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Higgins</LastName>
                    <ForeName>G A</ForeName>
                    <Initials>GA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Pharmacol Exp Ther</MedlineTA>
            <NlmUniqueID>0376362</NlmUniqueID>
            <ISSNLinking>0022-3565</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C412895">4-((3-(5,6-dihydro-4H-(2,3')bipyridinyl-3-ylidene)propenyl)phenyl)dimethylamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C408128">AR-R 17779</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001952">Bridged Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C579167">Chrna7 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C579165">Chrna7 protein, rat</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018722">Nicotinic Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011759">Pyrrolidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013141">Spiro Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D064569">alpha7 Nicotinic Acetylcholine Receptor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>54-11-5</RegistryNumber>
                <NameOfSubstance UI="D009538">Nicotine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>PCL7Q9Q62Q</RegistryNumber>
                <NameOfSubstance UI="C100989">altinicline maleate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001952">Bridged Compounds</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000134">cerebrospinal fluid</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004594">Electrophysiology</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D066298">In Vitro Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008024">Ligands</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009538">Nicotine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018722">Nicotinic Agonists</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009865">Oocytes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011725">Pyridines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011759">Pyrrolidines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020318">Rats, Long-Evans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011978">Receptors, Nicotinic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012201">Reward</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012646">Self Administration</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013141">Spiro Compounds</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000134">cerebrospinal fluid</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014162">Transfection</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014982">Xenopus laevis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D064569">alpha7 Nicotinic Acetylcholine Receptor</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>8</Month>
                <Day>17</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2000</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>11</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>8</Month>
                <Day>17</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10945867</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20686158</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>08</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>11</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1545-7222</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>22</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Season>Summer</Season>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuropsychiatry and clinical neurosciences</Title>
                <ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Is methylphenidate-induced chorea responsive to chlorpromazine?</ArticleTitle>
            <Pagination>
                <MedlinePgn>352n.e20-352.e20</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.neuropsych.22.3.352-n.e20</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Machado</LastName>
                    <ForeName>Alvaro</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cerqueira</LastName>
                    <ForeName>João</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rodrigues</LastName>
                    <ForeName>Margarida</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soares-Fernandes</LastName>
                    <ForeName>João</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA>
            <NlmUniqueID>8911344</NlmUniqueID>
            <ISSNLinking>0895-0172</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018765">Dopamine Uptake Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>207ZZ9QZ49</RegistryNumber>
                <NameOfSubstance UI="D008774">Methylphenidate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>U42B7VYA4P</RegistryNumber>
                <NameOfSubstance UI="D002746">Chlorpromazine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002746">Chlorpromazine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002819">Chorea</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018492">Dopamine Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018765">Dopamine Uptake Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008774">Methylphenidate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>8</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>8</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">22/3/352-n.e20</ArticleId>
            <ArticleId IdType="doi">10.1176/appi.neuropsych.22.3.352-n.e20</ArticleId>
            <ArticleId IdType="pubmed">20686158</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">7474220</PMID>
        <DateCreated>
            <Year>1995</Year>
            <Month>12</Month>
            <Day>06</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1995</Year>
            <Month>12</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0098-7484</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>274</Volume>
                    <Issue>19</Issue>
                    <PubDate>
                        <Year>1995</Year>
                        <Month>Nov</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA</Title>
                <ISOAbbreviation>JAMA</ISOAbbreviation>
            </Journal>
            <ArticleTitle>In utero exposure to phenobarbital and intelligence deficits in adult men.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1518-25</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To test whether exposure to phenobarbital in utero is associated with deficits in intelligence scores in adult men and whether the magnitude of the postnatal effect is mediated by exposure parameters and/or postnatal environmental factors.</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">Two double-blind studies were conducted on independent samples of adult men prenatally exposed to phenobarbital and matched control samples using different measures of general intelligence. Based on data from control subjects, regression models were built relating intelligence scores to relevant pre-exposure matching variables and age at testing. Models generated predicted scores for each exposed subject. Group mean differences between the individually predicted and observed scores estimated exposure effects.</AbstractText>
                <AbstractText Label="SETTING" NlmCategory="METHODS">Copenhagen, Denmark.</AbstractText>
                <AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Exposed subjects were adult men born at the largest hospital in Copenhagen between 1959 and 1961 who were exposed to phenobarbital during gestation via maternal medical treatment and whose mothers had no history of a central nervous system disorder and no treatment during pregnancy with any other psychopharmacological drug. Study 1 included 33 men and study 2, 81 men. Controls were unexposed members of the same birth cohort matched on a wide spectrum of maternal variables recorded prenatally and perinatally. Controls for studies 1 and 2 included 52 and 101 men, respectively.</AbstractText>
                <AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">In study 1: Wechsler Adult Intelligence Scale (Danish version); in study 2: Danish Military Draft Board Intelligence Test (Børge Priens Prøve).</AbstractText>
                <AbstractText Label="RESULT" NlmCategory="RESULTS">Men exposed prenatally to phenobarbital had significantly lower verbal intelligence scores (approximately 0.5 SD) than predicted. Lower socioeconomic status and being the offspring of an &quot;unwanted&quot; pregnancy increased the magnitude of the negative effects. Exposure that included the last trimester was the most detrimental.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Phenobarbital exposure during early development can have long-term deleterious effects on cognitive performance. Detrimental environmental conditions can interact with prenatal biological insult to magnify negative outcomes. Physicians are urged to use increased caution in prescribing such medications during pregnancy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Reinisch</LastName>
                    <ForeName>J M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Kinsey Institute for Research in Sex, Gender, and Reproduction, Indiana University, Bloomington 47405, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanders</LastName>
                    <ForeName>S A</ForeName>
                    <Initials>SA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mortensen</LastName>
                    <ForeName>E L</ForeName>
                    <Initials>EL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rubin</LastName>
                    <ForeName>D B</ForeName>
                    <Initials>DB</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DA 05056</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HD 17655</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HD 20263</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>JAMA</MedlineTA>
            <NlmUniqueID>7501160</NlmUniqueID>
            <ISSNLinking>0098-7484</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YQE403BP4D</RegistryNumber>
                <NameOfSubstance UI="D010634">Phenobarbital</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003071">Cognition</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D003718">Denmark</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004777">Environment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004781">Environmental Exposure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006993">Hypnotics and Sedatives</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007360">Intelligence</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007361">Intelligence Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010634">Phenobarbital</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011248">Pregnancy Complications</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011263">Pregnancy Trimester, Third</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011297">Prenatal Exposure Delayed Effects</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012044">Regression Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012959">Socioeconomic Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1995</Year>
                <Month>11</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1995</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1995</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7474220</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20686159</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>08</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>11</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1545-7222</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>22</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Season>Summer</Season>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuropsychiatry and clinical neurosciences</Title>
                <ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mirtazapine-associated urinary retention.</ArticleTitle>
            <Pagination>
                <MedlinePgn>352o.e21-352.e22</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.neuropsych.22.3.352-o.e21</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Oulis</LastName>
                    <ForeName>Panagiotis</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leonardos</LastName>
                    <ForeName>Athanasios</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koulouris</LastName>
                    <ForeName>George C</ForeName>
                    <Initials>GC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Konstantakopoulos</LastName>
                    <ForeName>George</ForeName>
                    <Initials>G</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA>
            <NlmUniqueID>8911344</NlmUniqueID>
            <ISSNLinking>0895-0172</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>250PJI13LM</RegistryNumber>
                <NameOfSubstance UI="D008803">Mianserin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>A051Q2099Q</RegistryNumber>
                <NameOfSubstance UI="C035133">mirtazapine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003865">Depressive Disorder, Major</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008803">Mianserin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016055">Urinary Retention</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>8</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>8</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">22/3/352-o.e21</ArticleId>
            <ArticleId IdType="doi">10.1176/appi.neuropsych.22.3.352-o.e21</ArticleId>
            <ArticleId IdType="pubmed">20686159</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6710222</PMID>
        <DateCreated>
            <Year>1984</Year>
            <Month>05</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1984</Year>
            <Month>05</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0038-4348</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>77</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1984</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Southern medical journal</Title>
                <ISOAbbreviation>South. Med. J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Seizures due to nalidixic acid therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>539-40</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Poe</LastName>
                    <ForeName>T E</ForeName>
                    <Initials>TE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marion</LastName>
                    <ForeName>G S</ForeName>
                    <Initials>GS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jackson</LastName>
                    <ForeName>D S</ForeName>
                    <Initials>DS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>South Med J</MedlineTA>
            <NlmUniqueID>0404522</NlmUniqueID>
            <ISSNLinking>0038-4348</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>3B91HWA56M</RegistryNumber>
                <NameOfSubstance UI="D009268">Nalidixic Acid</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009268">Nalidixic Acid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014552">Urinary Tract Infections</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1984</Year>
                <Month>4</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1984</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1984</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6710222</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12404689</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>10</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>01</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0885-6222</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Human psychopharmacology</Title>
                <ISOAbbreviation>Hum Psychopharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A case of Meige dystonia induced by short-term quetiapine treatment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>197</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nishikawa</LastName>
                    <ForeName>Tadashi</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishioka</LastName>
                    <ForeName>Satoko</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Hum Psychopharmacol</MedlineTA>
            <NlmUniqueID>8702539</NlmUniqueID>
            <ISSNLinking>0885-6222</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>BGL0JSY5SI</RegistryNumber>
                <NameOfSubstance UI="C069541">quetiapine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003987">Dibenzothiazepines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008538">Meige Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012559">Schizophrenia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>10</Month>
                <Day>31</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>1</Month>
                <Day>17</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>10</Month>
                <Day>31</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12404689</ArticleId>
            <ArticleId IdType="doi">10.1002/hup.391</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">762037</PMID>
        <DateCreated>
            <Year>1979</Year>
            <Month>04</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1979</Year>
            <Month>04</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0160-6689</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>40</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1979</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of clinical psychiatry</Title>
                <ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neuroleptic malignant syndrome due to depot fluphenazine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>99-100</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The parenteral long-acting phenothiazines are drugs frequently used in the treatment of hospitalized and ambulatory psychiatric patients. The usual side effects of these drugs are familiar to psychiatrists. However, the &quot;Neuroleptic malignant syndrome&quot; reported in this paper can give rise to considerable diagnostic difficulty. The clinical characteristics and differential diagnosis of this syndrome are described with a care report. The need for prompt initiation of adequate therapy is stressed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Grunhaus</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sancovici</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rimon</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Clin Psychiatry</MedlineTA>
            <NlmUniqueID>7801243</NlmUniqueID>
            <ISSNLinking>0160-6689</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6RC5V8B7PO</RegistryNumber>
                <NameOfSubstance UI="D014282">Trihexyphenidyl</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S79426A41Z</RegistryNumber>
                <NameOfSubstance UI="D005476">Fluphenazine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003128">Coma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003692">Delayed-Action Preparations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005334">Fever</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005476">Fluphenazine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011618">Psychotic Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014282">Trihexyphenidyl</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1979</Year>
                <Month>2</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1979</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1979</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">762037</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9689277</PMID>
        <DateCreated>
            <Year>1998</Year>
            <Month>10</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1998</Year>
            <Month>10</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0001-5172</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>42</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>1998</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Acta anaesthesiologica Scandinavica</Title>
                <ISOAbbreviation>Acta Anaesthesiol Scand</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dose-related cardiovascular effects of amrinone and epinephrine in reversing bupivacaine-induced cardiovascular depression.</ArticleTitle>
            <Pagination>
                <MedlinePgn>698-706</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To ascertain the efficacy of amrinone and epinephrine in reversing bupivacaine-induced cardiovascular depression, we investigated the time course of recovery of cardiac function with 3 doses of both agents after bupivacaine administration.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">In sevoflurane-anaesthetized dogs, bupivacaine was infused intravenously at 1 mg.kg-1.min-1 until mean arterial pressure fell to 60 mmHg or less. The 3 doses of amrinone (1, 2, and 4 mg.kg-1) or the 3 doses of epinephrine (2, 5, and 10 micrograms.kg-1) were administered as a bolus in randomized order in each dog.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Amrinone improved maximum left ventricular dP/dt, a time constant of left ventricular isovolemic relaxation and cardiac index persistently and dose-relatedly. Amrinone increased heart rate and decreased left ventricular end-diastolic pressure and systemic vascular resistance index. Amrinone at 1 and 2 mg.kg-1 significantly increased mean arterial pressure, but amrinone at 4 mg.kg-1 did not. Epinephrine increased mean arterial pressure, maximum left ventricular dP/dt, and systemic vascular resistance dose-relatedly. The duration of action of epinephrine, peaking at 1 min and subsequently decreasing by 10 min after administration, did not differ among the groups. Epinephrine at all doses failed to improve a time constant of left ventricular isovolemic relaxation and cardiac index. ECG evidence of serious ventricular dysrhythmias was seen in 1 out of 6 dogs after administrating each dose of amrinone and in 3, 3 and 5 out of 6 dogs after administrating 2, 5 and 10 micrograms.kg-1 of epinephrine, respectively.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Bolus amrinone may have a certain efficacy in reversing bupivacaine-induced cardiovascular depression, and improving cardiac contractility and relaxation dose-relatedly. In contrast to amrinone, bolus epinephrine remains indispensable for resuscitation, causing a rapid, massive, transient and dose-related rise in blood pressure. However, the use of amrinone may be limited predominantly by a decrease in systemic vascular resistance, while the use of epinephrine may be limited predominantly by the generation of serious ventricular dysrhythmias and lack of effectiveness on cardiac index and on cardiac relaxation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Igarashi</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anesthesiology, Jichi Medical School, Tochigi, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hirabayashi</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saitoh</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fukuda</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shimizu</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mitsuhata</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>DENMARK</Country>
            <MedlineTA>Acta Anaesthesiol Scand</MedlineTA>
            <NlmUniqueID>0370270</NlmUniqueID>
            <ISSNLinking>0001-5172</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000779">Anesthetics, Local</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JUT23379TN</RegistryNumber>
                <NameOfSubstance UI="D000676">Amrinone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Y8335394RO</RegistryNumber>
                <NameOfSubstance UI="D002045">Bupivacaine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YKH834O4BH</RegistryNumber>
                <NameOfSubstance UI="D004837">Epinephrine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000676">Amrinone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000779">Anesthetics, Local</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002045">Bupivacaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002316">Cardiotonic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003864">Depression, Chemical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004837">Epinephrine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006339">Heart Rate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006439">Hemodynamics</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013318">Stroke Volume</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016277">Ventricular Function, Left</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1998</Year>
                <Month>8</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1998</Year>
                <Month>8</Month>
                <Day>5</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1998</Year>
                <Month>8</Month>
                <Day>5</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9689277</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12908569</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>08</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>10</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1726-4901</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>66</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of the Chinese Medical Association : JCMA</Title>
                <ISOAbbreviation>J Chin Med Assoc</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>276-81</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Brimonidine is a highly selective alpha-2 adrenergic receptor agonist with intraocular pressure (IOP) reducing effect. We conducted this study in Taiwan to compare the safety and efficacy ofbrimonidine 0.2% with timolol 0.5% for the treatment of glaucoma.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A prospective, randomized, single-masked, 1-month clinical efficacy and safety trial was conducted from March to September 2000. Forty glaucoma patients were enrolled--29 in the brimonidine group and 11 in the timolol group. Patients instilled their study medications twice daily for 4 weeks, and were followed at baseline visit, weeks 2 and 4. Demographic data, reduction of IOP, safety and adverse events were obtained and analyzed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Both drugs showed sustained ocular hypotensive efficacy in the study period. At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group. The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p &lt; 0.001). At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol. At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol. No significant between-group differences were seen at peak or trough at all visits. The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817). 17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events. Ocular allergy occurred in 10.3% of patients in brimonidine group. No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups. Mean systolic and diastolic blood pressure remained relatively stable in both groups except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure. However, brimonidine showed no significant difference in week 4 from baseline. The mean heart rate in the brimonidine group was relatively unchanged over the study period. Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma. It has a safe systemic profile with minimum effect on the heart.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Mei-Ju</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Ophthalmology, Taipei Veterans General Hospital, ROC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chou</LastName>
                    <ForeName>Joe Ching-Kuang</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsu</LastName>
                    <ForeName>Wen-Ming</ForeName>
                    <Initials>WM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Jorn-Hon</ForeName>
                    <Initials>JH</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China (Republic : 1949- )</Country>
            <MedlineTA>J Chin Med Assoc</MedlineTA>
            <NlmUniqueID>101174817</NlmUniqueID>
            <ISSNLinking>1726-4901</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000316">Adrenergic alpha-Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>817W3C6175</RegistryNumber>
                <NameOfSubstance UI="D013999">Timolol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E6GNX3HHTE</RegistryNumber>
                <NameOfSubstance UI="C015620">brimonidine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000316">Adrenergic alpha-Agonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000319">Adrenergic beta-Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000959">Antihypertensive Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005901">Glaucoma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011810">Quinoxalines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013999">Timolol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>8</Month>
                <Day>12</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>10</Month>
                <Day>18</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>8</Month>
                <Day>12</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12908569</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">4197360</PMID>
        <DateCreated>
            <Year>1973</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1973</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0041-008X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>24</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1973</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology and applied pharmacology</Title>
                <ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sensitization to epinephrine-induced ventricular fibrillation produced by probucol in dogs.</ArticleTitle>
            <Pagination>
                <MedlinePgn>594-602</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Marshall</LastName>
                    <ForeName>F N</ForeName>
                    <Initials>FN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lewis</LastName>
                    <ForeName>J E</ForeName>
                    <Initials>JE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
            <NlmUniqueID>0416575</NlmUniqueID>
            <ISSNLinking>0041-008X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010636">Phenols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>P3CTH044XJ</RegistryNumber>
                <NameOfSubstance UI="D011341">Probucol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YKH834O4BH</RegistryNumber>
                <NameOfSubstance UI="D004837">Epinephrine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000924">Anticholesteremic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004562">Electrocardiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004837">Epinephrine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000882">Haplorhini</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006339">Heart Rate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008251">Macaca</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010636">Phenols</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011341">Probucol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012119">Respiration</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014693">Ventricular Fibrillation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1973</Year>
                <Month>4</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1973</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1973</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">4197360</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2785443</PMID>
        <DateCreated>
            <Year>1989</Year>
            <Month>06</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1989</Year>
            <Month>06</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0278-2677</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1989</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical pharmacy</Title>
                <ISOAbbreviation>Clin Pharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Seizure activity associated with fluoxetine therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>296-8</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Weber</LastName>
                    <ForeName>J J</ForeName>
                    <Initials>JJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy Practice, College of Pharmacy, University of Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Clin Pharm</MedlineTA>
            <NlmUniqueID>8207437</NlmUniqueID>
            <ISSNLinking>0278-2677</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012459">Salicylates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>01K63SUP8D</RegistryNumber>
                <NameOfSubstance UI="D005473">Fluoxetine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004569">Electroencephalography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005473">Fluoxetine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012459">Salicylates</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1989</Year>
                <Month>4</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1989</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1989</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2785443</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2144538</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>10</Month>
            <Day>17</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>10</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0272-846X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>10</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1990</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of clinical neuro-ophthalmology</Title>
                <ISOAbbreviation>J Clin Neuroophthalmol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Penicillamine-induced ocular myasthenia gravis in rheumatoid arthritis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>201-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We report a case of a 47-year-old woman with rheumatoid arthritis who developed ocular myasthenia gravis during penicillamine treatment. Her serum contained elevated titers of acetylcholine receptor antibodies, and her symptoms resolved 8 weeks after discontinuation of penicillamine. We review the clinical and laboratory features of this syndrome of penicillamine-induced myasthenia gravis and discuss its pathophysiology and treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>G T</ForeName>
                    <Initials>GT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Neurology, Brigham and Women's Hospital, Boston, MA 02115.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bienfang</LastName>
                    <ForeName>D C</ForeName>
                    <Initials>DC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Clin Neuroophthalmol</MedlineTA>
            <NlmUniqueID>8109051</NlmUniqueID>
            <ISSNLinking>0272-846X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011950">Receptors, Cholinergic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>GNN1DV99GX</RegistryNumber>
                <NameOfSubstance UI="D010396">Penicillamine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001172">Arthritis, Rheumatoid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004172">Diplopia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009157">Myasthenia Gravis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015835">Ocular Motility Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009801">Oculomotor Muscles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010396">Penicillamine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011950">Receptors, Cholinergic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>9</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2144538</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6724856</PMID>
        <DateCreated>
            <Year>1984</Year>
            <Month>07</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1984</Year>
            <Month>07</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0021-1265</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>153</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1984</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Irish journal of medical science</Title>
                <ISOAbbreviation>Ir J Med Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Metabolic abnormalities associated with tobramycin therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>96-9</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Watson</LastName>
                    <ForeName>A J</ForeName>
                    <Initials>AJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watson</LastName>
                    <ForeName>M M</ForeName>
                    <Initials>MM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Keogh</LastName>
                    <ForeName>J A</ForeName>
                    <Initials>JA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>IRELAND</Country>
            <MedlineTA>Ir J Med Sci</MedlineTA>
            <NlmUniqueID>7806864</NlmUniqueID>
            <ISSNLinking>0021-1265</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>I38ZP9992A</RegistryNumber>
                <NameOfSubstance UI="D008274">Magnesium</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>VZ8RRZ51VK</RegistryNumber>
                <NameOfSubstance UI="D014031">Tobramycin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006996">Hypocalcemia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007008">Hypokalemia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008274">Magnesium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008275">Magnesium Deficiency</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009399">Nephrons</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014031">Tobramycin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1984</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1984</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1984</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6724856</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2976372</PMID>
        <DateCreated>
            <Year>1989</Year>
            <Month>04</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1989</Year>
            <Month>04</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0012-6578</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>1988</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Drug intelligence &amp; clinical pharmacy</Title>
                <ISOAbbreviation>Drug Intell Clin Pharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Paresthesia and back pain in a patient receiving vancomycin during hemodialysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>784-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A 36-year-old woman was admitted for initiation of hemodialysis for chronic renal failure. Two days after catheter placement the patient developed a fever that persisted and resulted in subsequent removal of the catheter. Although blood cultures were negative, cultures of the catheter tip were positive for Staphylococcus epidermidis. An initial vancomycin dose was well tolerated, but the patient later experienced numbness and tingling of her lower back accompanied by pain ten minutes after initiation of the second dose. Symptoms abated when the vancomycin infusion was discontinued, and the drug was subsequently well tolerated when reinstituted at a slower infusion rate. Similar symptoms were observed five minutes into a vancomycin infusion a week later that also resolved after decreasing the infusion rate. Patients on hemodialysis receiving vancomycin should be carefully monitored during drug administration for the development of paresthesia and spasmodic lower back pain.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cohen</LastName>
                    <ForeName>L G</ForeName>
                    <Initials>LG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Brigham and Women's Hospital, Boston, MA 02115.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Souney</LastName>
                    <ForeName>P F</ForeName>
                    <Initials>PF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taylor</LastName>
                    <ForeName>S J</ForeName>
                    <Initials>SJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Drug Intell Clin Pharm</MedlineTA>
            <NlmUniqueID>0212457</NlmUniqueID>
            <ISSNLinking>0012-6578</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>6Q205EH1VU</RegistryNumber>
                <NameOfSubstance UI="D014640">Vancomycin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001416">Back Pain</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010292">Paresthesia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D006435">Renal Dialysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014640">Vancomycin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1988</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1988</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1988</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2976372</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9689271</PMID>
        <DateCreated>
            <Year>1998</Year>
            <Month>10</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1998</Year>
            <Month>10</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0001-5172</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>42</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>1998</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Acta anaesthesiologica Scandinavica</Title>
                <ISOAbbreviation>Acta Anaesthesiol Scand</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Vomiting, retching, headache and restlessness after halothane-, isoflurane- and enflurane-based anaesthesia. An analysis of pooled data following ear, nose, throat and eye surgery.</ArticleTitle>
            <Pagination>
                <MedlinePgn>658-63</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Isoflurane has exceeded halothane and enflurane in usage. A literature search, however, revealed no data comparing the effects on emesis, headache and restlessness of these three agents.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">With hospital ethics committee approval and patient consent, a prospective, randomised, double-blind study of 556 patients undergoing ENT and eye surgery was undertaken to evaluate the effects of halothane, isoflurane and enflurane on vomiting, retching, headache and restlessness until 24 h after anaesthesia. Balanced general anaesthesia was administered comprising benzodiazepine premedication, induction with thiopentone-atracurium-morphine (ENT patients) or fentanyl (eye patients), controlled ventilation and maintenance with either halothane 0.4-0.6 vol% (n = 186), isoflurane 0.6-0.8 vol% (n = 184) or enflurane 0.8-1 vol% (n = 186) in nitrous oxide 67% and oxygen.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The three study groups were comparable, and comprised comparable subgroups having ear, nose, throat, intraocular and non-intraocular surgery. During early recovery from anaesthesia, the respective requirements for halothane, isoflurane and enflurane for analgesia (7%, 9% and 10%), frequency of emesis (6%, 8% and 8%), antiemetic requirements (1%, 1% and 2%), restlessness-pain scores and time spent in the recovery ward (27 SD 10, 31 SD 12 and 26 SD 9 min) were similar. During the ensuing 24-h postoperative period, patients who had isoflurane experienced emesis less often than those who had halothane (36% vs 46%, P &lt; 0.025) but did so with similar frequency to those who had enflurane (46% vs 41%). Antiemetic requirements were least in those given isoflurane (isoflurane 12%, halothane and enflurane 23% each, P &lt; 0.005), but headache and analgesic requirements were similar.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Isoflurane induces less postoperative emesis than halothane, but headache is similarly frequent after anaesthesia with any of these agents.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>van den Berg</LastName>
                    <ForeName>A A</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anaesthesia, Riyadh Armed Forces Hospital, Kingdom of Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Honjol</LastName>
                    <ForeName>N M</ForeName>
                    <Initials>NM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mphanza</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rozario</LastName>
                    <ForeName>C J</ForeName>
                    <Initials>CJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Joseph</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>DENMARK</Country>
            <MedlineTA>Acta Anaesthesiol Scand</MedlineTA>
            <NlmUniqueID>0370270</NlmUniqueID>
            <ISSNLinking>0001-5172</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018685">Anesthetics, Inhalation</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000932">Antiemetics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>91I69L5AY5</RegistryNumber>
                <NameOfSubstance UI="D004737">Enflurane</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>CYS9AKD70P</RegistryNumber>
                <NameOfSubstance UI="D007530">Isoflurane</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>UQT9G45D1P</RegistryNumber>
                <NameOfSubstance UI="D006221">Halothane</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017109">Akathisia, Drug-Induced</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000768">Anesthesia, General</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018685">Anesthetics, Inhalation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000932">Antiemetics</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004737">Enflurane</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006221">Halothane</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006261">Headache</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007530">Isoflurane</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013508">Ophthalmologic Surgical Procedures</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013517">Otorhinolaryngologic Surgical Procedures</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014839">Vomiting</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1998</Year>
                <Month>8</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1998</Year>
                <Month>8</Month>
                <Day>5</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1998</Year>
                <Month>8</Month>
                <Day>5</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9689271</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1421048</PMID>
        <DateCreated>
            <Year>1992</Year>
            <Month>12</Month>
            <Day>17</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1992</Year>
            <Month>12</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0753-3322</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>46</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1992</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Biomedicine &amp; pharmacotherapy = Biomédecine &amp; pharmacothérapie</Title>
                <ISOAbbreviation>Biomed. Pharmacother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Minocycline and benign intracranial hypertension.</ArticleTitle>
            <Pagination>
                <MedlinePgn>171-2</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A case is reported of a 16-year-old girl who developed benign intracranial hypertension, with severe bilateral papilledema after minocycline therapy. A lumboperitoneal bypass was carried out in view of the ophthalmologic signs and the pressure of cerebrospinal fluid.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Donnet</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service de neurochirurgie, Hôpital de la Timone, Marseille, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dufour</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Graziani</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grisoli</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>FRANCE</Country>
            <MedlineTA>Biomed Pharmacother</MedlineTA>
            <NlmUniqueID>8213295</NlmUniqueID>
            <ISSNLinking>0753-3322</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>FYY3R43WGO</RegistryNumber>
                <NameOfSubstance UI="D008911">Minocycline</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008911">Minocycline</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011559">Pseudotumor Cerebri</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1421048</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">5570417</PMID>
        <DateCreated>
            <Year>1971</Year>
            <Month>11</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1971</Year>
            <Month>11</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0012-3714</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>32</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>1971</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Diseases of the nervous system</Title>
                <ISOAbbreviation>Dis Nerv Syst</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Renal functional damage during the course of lithium therapy. (A case report with renal biopsy findings).</ArticleTitle>
            <Pagination>
                <MedlinePgn>483-5</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Salomon</LastName>
                    <ForeName>M I</ForeName>
                    <Initials>MI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>King</LastName>
                    <ForeName>E J</ForeName>
                    <Initials>EJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gallo</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Dis Nerv Syst</MedlineTA>
            <NlmUniqueID>0370666</NlmUniqueID>
            <ISSNLinking>0012-3714</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>9FN79X2M3F</RegistryNumber>
                <NameOfSubstance UI="D008094">Lithium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001161">Arteriosclerosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001806">Blood Urea Nitrogen</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008094">Lithium</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009325">Nausea</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009400">Nephrosclerosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011507">Proteinuria</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014202">Tremor</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014839">Vomiting</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1971</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1971</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1971</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">5570417</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">7248968</PMID>
        <DateCreated>
            <Year>1981</Year>
            <Month>09</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1981</Year>
            <Month>09</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0008-5472</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>41</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>1981</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer research</Title>
                <ISOAbbreviation>Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of L-tryptophan and sodium saccharin on urinary tract carcinogenesis initiated by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3100-3</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The effect of sodium saccharin (SAC) or L-tryptophan (LT) on urinary bladder carcinogenesis initiated by feeding N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) for 4 weeks as 0.2% of the diet to male F344 weanling rats was evaluated. SAC was fed as 5% of the diet, and LT was 2% of the diet. FANFT fed for 4 weeks followed by 100 weeks of control diet did not produce any carcinomas; one of 25 rats developed a bladder papilloma. Of 26 rats fed SAC for 100 weeks after FANFT, two developed papillomas, and five developed carcinomas (p less than 0.03). Of 26 rats fed LT for 100 weeks after FANFT, three developed papillomas, and two developed carcinomas (p greater than 0.1) Eight rats fed FANFT for 72 weeks all developed bladder carcinomas, but rats fed control diet alone, control diet with SAC, or control diet with LT did not develop any bladder tumors. Scanning electron microscopic examination of Week 104 of the experiment showed the presence of pleomorphic microvilli on the bladder surface of some rats fed SAC of LT whether following 4 weeks of control diet alone or 4 weeks of FANFT. Four weeks of FANFT feeding, a lower dose than used previously in our studies, appears to be a subcarcinogenic level. Under these experimental conditions, the promoting activity of SAC is demonstrated with statistical significance. The results with LT were not statistically significant.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fukushima</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Friedell</LastName>
                    <ForeName>G H</ForeName>
                    <Initials>GH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacobs</LastName>
                    <ForeName>J B</ForeName>
                    <Initials>JB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cohen</LastName>
                    <ForeName>S M</ForeName>
                    <Initials>SM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>CA15945</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Cancer Res</MedlineTA>
            <NlmUniqueID>2984705R</NlmUniqueID>
            <ISSNLinking>0008-5472</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7N99PZG62O</RegistryNumber>
                <NameOfSubstance UI="D005200">FANFT</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8DUH1N11BX</RegistryNumber>
                <NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>FST467XS7D</RegistryNumber>
                <NameOfSubstance UI="D012439">Saccharin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002295">Carcinoma, Transitional Cell</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D003043">Cocarcinogenesis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D005200">FANFT</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D012439">Saccharin</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D013844">Thiazoles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D014364">Tryptophan</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001749">Urinary Bladder Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1981</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1981</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1981</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7248968</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
